Literature DB >> 3015640

In vivo 'enkephalinase' inhibition by acetorphan in human plasma and CSF.

M G Spillantini, P Geppetti, M Fanciullacci, S Michelacci, J M Lecomte, F Sicuteri.   

Abstract

Thiorphan, the potent inhibitor of 'enkephalinase', has shown some analgesic properties in experimental animals and in man. The possibility that the intravenous infusion of acetorphan, a prodrug of thiorphan (26 micrograms/kg per min for 60 min), can inhibit plasma and cerebrospinal fluid (CSF) enkephalinase in man in vivo was investigated. A decrease of approximately 65% in enzyme activity was observed in both plasma and CSF. Acetorphan did not induce any significant variation of plasma angiotensin-converting enzyme activity.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3015640     DOI： 10.1016/0014-2999(86)90094-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


  12 in total

1.  Effect of neutral endopeptidase inhibitor on airway function and bronchial responsiveness in asthmatic subjects.

Authors:  G M Nichol; B J O'Connor; J M Lecomte; K F Chung; P J Barnes
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Neutral endopeptidase (EC 3.4.24.11) in labial salivary glands in healthy controls and in patients with Sjögren's syndrome.

Authors:  Y T Konttinen; J Törnwall; P Kemppinen; H Uusitalo; T Sorsa; M Hukkanen; J M Polak
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

3.  Effects of aerosolised substance P on lung resistance in guinea-pigs: a comparison between inhibition of neutral endopeptidase and angiotensin-converting enzyme.

Authors:  J O Lötvall; B E Skoogh; P J Barnes; K F Chung
Journal:  Br J Pharmacol       Date:  1990-05       Impact factor: 8.739

4.  A new procedure for thioester deprotection using thioglycolic acid in both homogeneous and heterogeneous phase.

Authors:  Valentina Villamil; Cecilia Saiz; Graciela Mahler
Journal:  Tetrahedron       Date:  2021-07-10       Impact factor: 2.388

Review 5.  Racecadotril versus loperamide: antidiarrheal research revisited.

Authors:  S Huighebaert; F Awouters; G N J Tytgat
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

6.  Tubular proteinuria and enzymuria following open heart surgery.

Authors:  John Blaikley; Peter Sutton; Mary Walter; Martha Lapsley; Anthony Norden; Wilf Pugsley; Robert Unwin
Journal:  Intensive Care Med       Date:  2003-07-10       Impact factor: 17.440

7.  Neutral endopeptidase (3.4.24.11) in plasma and synovial fluid of patients with rheumatoid arthritis. A marker of disease activity or a regulator of pain and inflammation?

Authors:  M Matucci-Cerinic; A Lombardi; G Leoncini; A Pignone; L Sacerdoti; M G Spillantini; G Partsch
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

8.  Reduced circulating levels of angiotensin-(1--7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control.

Authors:  Alberto Pignone; Angela Del Rosso; K Bridget Brosnihan; Federico Perfetto; Riccardo Livi; Ginevra Fiori; Serena Guiducci; Marina Cinelli; Veronica Rogai; Alessio Tempestini; Francesca Bartoli; Sergio Generini; Carlos M Ferrario; Marco Matucci Cerinic
Journal:  Ann Rheum Dis       Date:  2007-03-14       Impact factor: 19.103

9.  A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril.

Authors:  Marion Eberlin; Tobias Mück; Martin C Michel
Journal:  Front Pharmacol       Date:  2012-05-30       Impact factor: 5.810

10.  Evaluating the cost utility of racecadotril for the treatment of acute watery diarrhea in children: the RAWD model.

Authors:  Tamlyn Anne Rautenberg; Ute Zerwes; Douglas Foerster; Rick Aultman
Journal:  Clinicoecon Outcomes Res       Date:  2012-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.